-
Mashup Score: 4Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis - 5 day(s) ago
Abstract. Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Advancing Global Pharmacoequity in Oncology - 6 day(s) ago
This Special Communication proposes building regional technology transfer hubs, streamlining and increasing the use of compulsory licenses, and enhancing price transparency as a way to meaningfully reduce cancer drug prices globally, especially for low- and middle-income countries.
Source: jamanetwork.comCategories: General Medicine News, Partners & KOLsTweet-
RT @pash22: Advancing Global Pharmacoequity in Oncology https://t.co/TW0Ndf6iMF via @Eddie_Cliff et al https://t.co/ReOi20AvHy
-
-
Mashup Score: 47Advancing Global Pharmacoequity in Oncology - 8 day(s) ago
This Special Communication proposes building regional technology transfer hubs, streamlining and increasing the use of compulsory licenses, and enhancing price transparency as a way to meaningfully reduce cancer drug prices globally, especially for low- and middle-income countries.
Source: jamanetwork.comCategories: General Medicine News, Partners & KOLsTweet-
Just out @JAMAOnc led by @ParsaErfan We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity https://t.co/CZTQBFzfgy https://t.co/ANvDp3EABd
-
-
Mashup Score: 88
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
AutoSCT vs alloSCT in CR1 for PTCL Long term f/up of AATT RCT @JCO_ASCO 7 yr EFS: allo 38% v auto 34% 7 yr OS: allo 55% v auto 61% 15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23% https://t.co/QqYsjK5OJw Allo the goal in fit PTCL https://t.co/cwtsJtiRZo
-
-
Mashup Score: 88
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
AutoSCT vs alloSCT in CR1 for PTCL Long term f/up of AATT RCT @JCO_ASCO 7 yr EFS: allo 38% v auto 34% 7 yr OS: allo 55% v auto 61% 15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23% https://t.co/QqYsjK5OJw Allo the goal in fit PTCL https://t.co/cwtsJtiRZo
-
-
Mashup Score: 14Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival - 18 day(s) ago
Oncology drug development has benefited from the ability in many cases to directly measure disease burden by clinical and radiographic measures. Tumor-based end points including objective response rate (ORR) and progression-free survival (PFS) have been implemented as early clinical end points and have been extensively used in the evaluation of anticancer agents. However, recent oncology trials have highlighted a lack of correlation between these early efficacy end points and overall survival (OS). Six
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Good question @laura_korin! A topic I am very passionate about: acceptability of surrogate endpoints. To me varies with setting: frontline CLL, MM, FL all v reasonable OS must still be reported & comparable - https://t.co/laBHrEfZEW Aggressive dz (e.g. AML) want OS -… https://t.co/EJ1aVhT31S https://t.co/pB9uDHsznE
-
-
Mashup Score: 1A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas - 19 day(s) ago
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @Diva_Baggio: Nice conceptual framework of PTCL https://t.co/OXVZSh5RYo @BloodJournal Innate PTCL: - γδ T cells, NK cells - involve sk…
-
-
Mashup Score: 23How I Treat patients with AML using azacitidine and venetoclax - 28 day(s) ago
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating a
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
So great to have the fantastic Prof Andrew Wei on @BloodCancerTalk to talk about venetoclax in AML - perfectly timed with the release of his How I Treat article in @BloodJournal https://t.co/809QA2r1R9 @PeterMacRes @thelimbichaem @Haem_pmcc_rmh #leusm @MAF_Dawson @WEHI_research https://t.co/roCupYMsHF
-
-
Mashup Score: 23How I Treat patients with AML using azacitidine and venetoclax - 28 day(s) ago
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating a
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
So great to have the fantastic Prof Andrew Wei on @BloodCancerTalk to talk about venetoclax in AML - perfectly timed with the release of his How I Treat article in @BloodJournal https://t.co/809QA2r1R9 @PeterMacRes @thelimbichaem @Haem_pmcc_rmh #leusm @MAF_Dawson @WEHI_research https://t.co/roCupYMsHF
-
-
Mashup Score: 23How I Treat patients with AML using azacitidine and venetoclax - 28 day(s) ago
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating a
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
So great to have the fantastic Prof Andrew Wei on @BloodCancerTalk to talk about venetoclax in AML - perfectly timed with the release of his How I Treat article in @BloodJournal https://t.co/809QA2r1R9 @PeterMacRes @thelimbichaem @Haem_pmcc_rmh #leusm @MAF_Dawson @WEHI_research https://t.co/roCupYMsHF
-
Full open access article available here: https://t.co/F5cQQPzWyt #mmsm #myeloma @BloodAdvances